Genmab: GEN3014's Demise And Implications For The HexaBody Platform
Genmab wisely chose not to pursue GEN3014 further, focusing instead on its existing pipeline projects. Click here to read an ...
BioNTech (NASDAQ:BNTX) Now Covered by Analysts at Citigroup
Citigroup started coverage on shares of BioNTech (NASDAQ:BNTX – Free Report) in a report issued on Thursday morning, Marketbeat Ratings reports. The brokerage issued a buy rating and a $145.00 target ...
Analysts Set Expectations for BioNTech FY2024 Earnings
Analysts at HC Wainwright issued their FY2024 earnings per share (EPS) estimates for shares of BioNTech in a research report ...